Cannabidiol

Generic Name: Cannabidiol

Brand Names: Epidiolex, Sativex, Epidyolex

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 13956-29-1

Unique Ingredient Identifier: 19GBJ60SN5

Background: Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...

Indication: When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...

Associated Conditions: Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain

Associated Therapies: -

Clinical Trials

Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

Phase 2

Terminated

Conditions: Prader-Willi Syndrome

Interventions: Drug: Cannabidiol
Drug: Placebo

First Posted Date: 2016-07-26

Last Posted Date: 2023-08-01

Lead Sponsor: Radius Pharmaceuticals, Inc.

Target Recruit Count: 7

Registration Number: NCT02844933

Locations: 🇺🇸
The University of Kansas , Medical Center, Kansas City, Kansas, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 4 locations

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: cannabidiol

First Posted Date: 2016-06-30

Last Posted Date: 2019-02-19

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 13

Registration Number: NCT02818777

Locations: 🇺🇸
University of Colorado School of Medicine, Aurora, Colorado, United States

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy

Phase 1

Terminated

Conditions: Lennox-Gastaut Syndrome
Dravet Syndrome

Interventions: Procedure: 12-Lead ECG
Drug: Cannabidiol

First Posted Date: 2016-06-28

Last Posted Date: 2022-08-30

Lead Sponsor: Gillette Children's Specialty Healthcare

Target Recruit Count: 2

Registration Number: NCT02815540

Locations: 🇺🇸
Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States

A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy

Phase 3

Active, not recruiting

Conditions: Epilepsy

Interventions: Drug: Cannabidiol
Drug: Placebo

First Posted Date: 2016-05-26

Last Posted Date: 2023-11-29

Lead Sponsor: Antonio Waldo Zuardi

Target Recruit Count: 126

Registration Number: NCT02783092

Locations: 🇧🇷
Unidade de Pesquisa Clínica HCRP-USP, Ribeirao Preto, Sao Paulo, Brazil

Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2016-04-26

Last Posted Date: 2021-05-12

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 18

Registration Number: NCT02751359

Locations: 🇺🇸
Cooper, New York, New York, United States

University of Alabama at Birmingham (UAB) Adult CBD Program

Phase 1

Completed

Conditions: Seizures
Epilepsy

Interventions: Drug: Epidiolex

First Posted Date: 2016-03-07

Last Posted Date: 2020-05-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 80

Registration Number: NCT02700412

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

University of Alabama at Birmingham (UAB) Pediatric CBD Program

Phase 1

Completed

Conditions: Seizures
Epilepsy

Interventions: Drug: Epidiolex

First Posted Date: 2016-03-01

Last Posted Date: 2020-04-10

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 89

Registration Number: NCT02695537

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy

Conditions: Epilepsy

First Posted Date: 2016-01-21

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Registration Number: NCT02660255

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Cannabidiol and Cocaine Craving/Dependence

Phase 2

Completed

Conditions: Substance Use Disorder
Cocaine Dependence
Withdrawal From Addictive Substance; Detoxification

Interventions: Drug: Cannabidiol

First Posted Date: 2015-09-24

Last Posted Date: 2020-10-23

Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Target Recruit Count: 79

Registration Number: NCT02559167

Locations: 🇨🇦
Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

Cannabidiol Treatment in Patients With Early Psychosis

Phase 2

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: Cannabidiol
Drug: Placebo

First Posted Date: 2015-07-21

Last Posted Date: 2022-09-06

Lead Sponsor: Yale University

Target Recruit Count: 18

Registration Number: NCT02504151

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy